Cytos Biotechnology News

After 19 years of fruitless drug development work capped by the failure of a Phase IIb study of its experimental asthma therapy, Cytos Biotechnology is ready to call it quits.

After closing out a failed Novartis partnership in January, Cytos Biotechnology has registered some upbeat data from a mid-stage study of its lead drug against allergic asthma. On the news, Zurich-based Cytos' shares jumped 14% as of early this morning, Bloomberg reported.

Swiss biotech Cytos has scraped together $40 million to advance its pipeline of immunotherapies, giving itself much-needed capital after a cash crunch last summer forced the company to ax most of its staff.

Cytos Biotechnology built a staff of 82, partnered with two Big Pharma companies and pushed a promising therapeutic vaccine well into Phase II. But today the 16-year-old Swiss developer is scrambling

The Wall Street Journal has taken an in-depth look at the trials and tribulations faced by a group of biotech companies determined to develop a string of vaccines to treat various addictions.

Swiss researchers claim to have found a 'one size fits all' allergy shot for hay fever, asthma and eczema, adding that it could be available within four to five years, the Telegraph reports. The

Switzerland's Cytos Biotechnology (CYTN) stock was punished on the news that it's anti-smoking vaccine failed to hit its primary endpoint in a Phase II trial. This endpoint was defined as a

Cytos Biotechnology (CYTN) says it expects to close a partnering deal for its allergy drug program in 2010. The Swiss company revealed in July positive mid-stage results for CYT003-QbG10, an

Shares of Cytos Biotechnology jumped on the news that its mid-stage study of an experimental allergy vaccine hit its primary endpoint. Analysts were quick to leap on the data, noting that positive